神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

休市中 07-24 16:00:00 EDT

175.77

+1.62

+0.93%

盘后175.77

+0.000.00%

19:46 EDT

最高177.30	最低173.43	成交量112.95万
今开174.25	昨收174.15	日振幅2.22%
总市值176.41亿	流通市值174.27亿	总股本1.00亿
成交额1.98亿	换手率1.14%	流通股本9,915万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":175.77,"timestamp":1784923200000,"preClose":174.15,"halted":0,"volume":1129509,"hourTrading":{"tag":"盘后","latestPrice":175.77,"preClose":175.77,"latestTime":"19:46 EDT","volume":144206,"amount":25347103.6575,"timestamp":1784936809924,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.009302325581395375,"floatShares":99145819,"shares":100363463,"eps":6.502496,"marketStatus":"休市中","change":1.62,"latestTime":"07-24 16:00:00 EDT","open":174.25,"high":177.3,"low":173.43,"amount":198430051.52835,"amplitude":0.022222,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.502496,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":832824000000,"exchange":"NASDAQ","adjPreClose":174.15,"preHourTrading":{"tag":"盘前","latestPrice":174.06,"preClose":174.15,"latestTime":"09:29 EDT","volume":671,"amount":116182.17379999999,"timestamp":1784899799999,"change":-0.09,"changeRate":-0.000517,"amplitude":0.016308},"postHourTrading":{"tag":"盘后","latestPrice":175.77,"preClose":175.77,"latestTime":"19:46 EDT","volume":144206,"amount":25347103.6575,"timestamp":1784936809924,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.025275215442237,"impliedVol":0.4119,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/NBIX","defaultTab":"news","newsList":[{"id":"1105854416","title":"财报前瞻｜神经分泌生物科学本季度营收预计增34.84%，机构观点看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1105854416","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105854416?lang=zh_cn&edition=full","pubTime":"2026-07-23 12:07","pubTimestamp":1784779678,"startTime":"0","endTime":"0","summary":"神经分泌生物科学将于2026年07月30日发布最新季度财报，市场预期营收和盈利延续高增势头，核心产品动能与新产品商业化将成为关注焦点。市场一致预期本季度神经分泌生物科学总营收为8.80亿美元，同比增长34.84%；调整后每股收益为1.31美元，同比增长35.19%。结合本季度一致预期，营收预计8.80亿美元、同比增长34.84%，若核心产品的新患者启动与持续用药强度维持上季度水平或略有改善，收入端的可视性较好。当前机构观点以看多为主。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜神经分泌生物科学本季度营收预计增34.84%，机构观点看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132713140","title":"神经分泌生物科学启动Crinecerfont针对4岁以下经典先天性肾上腺皮质增生症患儿的2期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1132713140","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132713140?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:07","pubTimestamp":1782936442,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司已启动一项针对四岁以下经典先天性肾上腺皮质增生症（CAH）儿科患者的2期临床研究，以评估其候选药物Crinecerfont的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","NBIX","LU2065171402.SGD","LU2324357040.USD","LU0320765992.SGD","LU0154245756.USD","LU0823416689.USD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD","LU0154245673.USD","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108171843","title":"神经分泌生物科学公布迟发性运动障碍治疗新临床应答数据，强化Ingrezza®（缬苯那嗪）胶囊在广泛患者群体中的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1108171843","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108171843?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:06","pubTimestamp":1780949176,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公布了关于迟发性运动障碍治疗的最新临床意义应答数据。这些数据进一步证实了Ingrezza®（缬苯那嗪）胶囊在广泛患者群体中展现出的显著疗效。新信息强化了该疗法应对这一挑战性运动障碍的有效性，为更全面的患者管理提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","NBIX","LU0320765992.SGD","LU0154245673.USD","LU0109394709.USD","LU2065169927.USD","LU2065171402.SGD","LU0823416689.USD","LU0154245756.USD","LU2324357040.USD","LU0889565916.HKD","LU2065171311.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105742910","title":"异动解读｜神经分泌生物科学盘中上涨5.85%，机构看好Crenessity商业化前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1105742910","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105742910?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:16","pubTimestamp":1780503392,"startTime":"0","endTime":"0","summary":"消息面上，加拿大皇家银行资本市场近日将该公司目标价从180美元上调至183美元，维持跑赢大盘评级，并发布研报指出Crenessity商业化增长仍有更多上行空间。RBC对35位内分泌科医生的调查显示，受访医生目前平均在约23%的相关患者中使用Crenessity，预计到年底将提升至37%。RBC据此将Crenessity全年销售预期从7.34亿美元上调至7.5亿美元，显著高于市场约6.5亿美元的一致预期，认为即使在更保守的增长假设下该目标仍可实现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191847458","title":"异动解读 | Crenessity®专家建议发表，神经分泌生物科学盘前大涨5.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191847458","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191847458?lang=zh_cn&edition=full","pubTime":"2026-05-06 21:56","pubTimestamp":1778075761,"startTime":"0","endTime":"0","summary":"神经分泌生物科学（NBIX）今日盘前股价大涨5.86%，引起了市场的广泛关注。消息面上，神经分泌生物科学公司宣布，关于启动Crenessity®（Crinecerfont）治疗经典先天性肾上腺皮质增生症后如何减少糖皮质激素用量的专家建议已正式发表。该方案为临床医生提供了重要指导，旨在优化治疗策略并改善患者预后，这被视为公司在该药物研发和商业化进程中的积极进展，增强了投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100486194","title":"神经分泌生物科学公布专家建议：启动Crenessity®治疗经典先天性肾上腺皮质增生症后糖皮质激素减量方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1100486194","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100486194?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:31","pubTimestamp":1778070686,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司宣布，关于启动Crenessity®（Crinecerfont）治疗经典先天性肾上腺皮质增生症后如何减少糖皮质激素用量的专家建议已正式发表。该方案为临床医生提供了重要指导，旨在优化治疗策略并改善患者预后。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","LU0320765992.SGD","LU0154245673.USD","LU2324357040.USD","LU0154245756.USD","LU0823416689.USD","LU2065170008.USD","LU0109394709.USD","LU2065171402.SGD","BK4139","LU2065169927.USD","LU2065171311.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131770926","title":"神经分泌生物科学公布新调查结果：迟发性运动障碍对就业构成显著负担","url":"https://stock-news.laohu8.com/highlight/detail?id=1131770926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131770926?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:32","pubTimestamp":1777897948,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司近日发布了一项新的调查结果，该结果揭示了迟发性运动障碍对患者就业状况产生的显著负面影响。调查显示，这一神经系统疾病不仅严重影响患者的日常生活质量，更对其职业发展和工作能力构成了沉重负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","LU2065170008.USD","LU0320765992.SGD","LU2065171402.SGD","LU0154245756.USD","LU2065169927.USD","LU2324357040.USD","LU0109394709.USD","LU0823416689.USD","NBIX","BK4139","LU0889565916.HKD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134439642","title":"神经分泌生物科学启动评估NBIP-'2118的1期临床研究，该药物为促肾上腺皮质激素释放因子2型受体激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1134439642","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134439642?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:54","pubTimestamp":1777895680,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司宣布，已正式启动一项1期临床研究，旨在评估其在研药物NBIP-'2118。该药物是一种促肾上腺皮质激素释放因子2型受体激动剂。\n此项1期研究的初步数据预计将于2027年公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","NBIX","LU0320765992.SGD","LU0154245673.USD","LU0109394709.USD","LU2065169927.USD","LU2065171402.SGD","LU0823416689.USD","LU0154245756.USD","LU2324357040.USD","LU0889565916.HKD","LU2065171311.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100622320","title":"神经分泌生物科学启动评估Nbip-'2118的I期临床研究，该药物为促肾上腺皮质激素释放因子2型受体激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1100622320","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100622320?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:32","pubTimestamp":1777894337,"startTime":"0","endTime":"0","summary":"生物制药公司神经分泌生物科学宣布，正式启动一项I期临床研究，旨在评估其在研药物Nbip-'2118。该药物是一种促肾上腺皮质激素释放因子2型受体激动剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2065170008.USD","LU0889565916.HKD","LU0320765992.SGD","LU0823416689.USD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","NBIX","LU2065169927.USD","BK4139","LU0154245673.USD","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181164572","title":"神经分泌生物科学公布Crenessity®（Crinecerfont）两年新数据：证实对经典先天性肾上腺增生症儿科患者具有持久激素控制、减少糖皮质激素暴露及显著临床改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1181164572","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181164572?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:06","pubTimestamp":1777665978,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司最新公布的两年期临床研究数据显示，其研发的Crenessity®（Crinecerfont）在治疗经典先天性肾上腺增生症的儿科患者方面展现出持续疗效。该数据证实，该疗法能够实现持久的激素水平控制，显著降低患者对糖皮质激素的暴露剂量，并为患儿带来具有临床意义的症状改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","LU2065169927.USD","LU0320765992.SGD","LU0154245756.USD","LU0823416689.USD","LU2324357040.USD","LU0154245673.USD","LU0109394709.USD","LU2065170008.USD","LU2065171402.SGD","LU0889565916.HKD","LU2065171311.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625693674","title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2625693674","media":"智通财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625693674?lang=zh_cn&edition=full","pubTime":"2026-04-07 06:05","pubTimestamp":1775513144,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425299.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0154245673.USD","LU2065170008.USD","LU0320765992.SGD","LU2065171402.SGD","SLNO","LU0154245756.USD","LU2065169927.USD","LU2324357040.USD","LU0109394709.USD","LU0823416689.USD","NBIX","BK4139","LU0889565916.HKD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146320564","title":"特定条件下交易终止时 Soleno 将向 Neurocrine 支付9.53亿美元解约金","url":"https://stock-news.laohu8.com/highlight/detail?id=1146320564","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146320564?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:39","pubTimestamp":1775475553,"startTime":"0","endTime":"0","summary":"根据最新披露的协议条款，若此次并购交易因特定情形被迫终止，Soleno Therapeutics（SLNO）需向Neurocrine Biosciences（NBIX）支付高达9.53亿美元的解约费用。这一条款为交易设置了明确的风险对冲机制。\n该金额的设定反映出双方对交易价值的共同认知，同时也为可能出现的意外情况提供了契约保障。分析师指出，此类终止费条款在生物医药行业并购中较为常见，既能保护收购方利益，又体现了卖方的交易诚意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2065169927.USD","SLNO","LU0109394709.USD","LU2065170008.USD","BK4139","LU2324357040.USD","LU0154245673.USD","LU0823416689.USD","LU0889565916.HKD","LU0154245756.USD","LU2065171402.SGD","NBIX","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197470067","title":"Soleno Therapeutics股价盘前飙升30%，传神经分泌生物科学接近达成25亿美元收购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197470067","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197470067?lang=zh_cn&edition=full","pubTime":"2026-04-06 16:35","pubTimestamp":1775464514,"startTime":"0","endTime":"0","summary":"有报道称神经分泌生物科学（Neurocrine Biosciences）即将以约25亿美元的价格收购Soleno Therapeutics，这一消息推动后者股价在盘前交易中大幅上涨30%。市场对这笔潜在交易反应热烈，反映出投资者对两家公司战略整合前景的积极预期。\n此次收购若成功落地，将成为神经科学领域近年来的重要并购案例。神经分泌生物科学通过整合Soleno Therapeutics的研发管线，有望强化其在中枢神经系统治疗领域的布局。盘前交易量的显著增长，也体现出资本市场对行业资源整合的高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU0154245756.USD","LU2324357040.USD","LU0823416689.USD","LU0109394709.USD","BK4139","LU2065169927.USD","SLNO","NBIX","LU0889565916.HKD","LU2065171311.SGD","LU0154245673.USD","LU0320765992.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192207553","title":"Neurocrine Biosciences据报接近以逾25亿美元收购Soleno Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1192207553","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192207553?lang=zh_cn&edition=full","pubTime":"2026-04-06 11:24","pubTimestamp":1775445893,"startTime":"0","endTime":"0","summary":"据 Financial Times 报道，制药公司  $神经分泌生物科学(NBIX)$  正接近达成一项超过25亿美元的收购交易，目标为  $Soleno Therapeutics(SLNO)$ 。受消息影响，  $神经分泌生物科学(NBIX)$  夜盘跌3%， $Soleno Therapeutics(SLNO)$ 夜盘飙20%。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurocrine Biosciences据报接近以逾25亿美元收购Soleno Therapeutics","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112349305","title":"财报前瞻｜神经分泌生物科学营收预计同比增26.35%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1112349305","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112349305?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:23","pubTimestamp":1770171820,"startTime":"0","endTime":"0","summary":"神经分泌生物科学将于2026年02月11日发布财报，市场关注盈利能力与核心产品动能的延续情况。市场一致预期本季度神经分泌生物科学营收约为7.95亿美元，同比增26.35%；调整后每股收益约为1.91美元，同比增22.25%；息税前利润约为2.28亿美元，同比增13.04%。上一季度神经分泌生物科学营收7.95亿美元，同比增长27.78%；毛利率66.79%；归属于母公司净利润2.10亿美元，同比环比增长属性以工具数据为准，净利率26.36%；调整后每股收益2.04美元，同比增长64.52%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜神经分泌生物科学营收预计同比增26.35%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149008441","title":"神经分泌生物科学启动评估NBI-1065890治疗成人迟发性运动障碍的二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1149008441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149008441?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:33","pubTimestamp":1769434400,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司已正式启动一项二期临床试验，旨在评估其研究性药物NBI-1065890在成人迟发性运动障碍患者中的疗效与安全性。这项研究的启动标志着公司在推进其神经系统疾病治疗产品管线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","NBIX","LU0823416689.USD","LU2065170008.USD","LU2065171311.SGD","LU0320765992.SGD","LU0154245673.USD","LU2065171402.SGD","LU0154245756.USD","LU2065169927.USD","BK4139","LU2324357040.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510898521","title":"神经分泌生物科学盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510898521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510898521?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:25","pubTimestamp":1739208314,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时25分，神经分泌生物科学股票出现异动，股价快速跳水5.01%。截至发稿，该股报116.48美元/股，成交量119.903万股，换手率1.18%，振幅7.49%。神经分泌生物科学股票所在的制药行业中，整体跌幅为0.65%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211012514abc9caca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211012514abc9caca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065171311.SGD","BK4139","LU2324357040.USD","LU0889565916.HKD","LU2065170008.USD","NBIX","LU0823416689.USD","LU2065171402.SGD","LU2065169927.USD","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510688998","title":"Guggenheim：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由165.00美元调整至163.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510688998","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510688998?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:01","pubTimestamp":1739196109,"startTime":"0","endTime":"0","summary":"Guggenheim：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由165.00美元调整至163.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/10220148063374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510472180","title":"神经分泌生物科学2024财年实现净利润3.41亿美元，同比增加36.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510472180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510472180?lang=zh_cn&edition=full","pubTime":"2025-02-10 00:01","pubTimestamp":1739116869,"startTime":"0","endTime":"0","summary":"2月10日，神经分泌生物科学公布财报，公告显示公司2024财年净利润为3.41亿美元，同比增加36.40%；其中营业收入为23.55亿美元，同比增加24.80%，每股基本收益为3.40美元。从资产负债表来看，神经分泌生物科学总负债11.29亿美元，其中短期债务0.00美元，资产负债比为3.30，流动比率为3.40。机构评级：截至2025年2月10日，当前有23家机构对神经分泌生物科学目标价做出预测，其中目标均价为169.78美元，其中最低目标价为140.00美元，最高目标价为192.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000149a23f5e13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000149a23f5e13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509776513","title":"加拿大皇家银行：维持Neurocrine Biosciences(NBIX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由154.00美元调整至148.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509776513","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509776513?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:23","pubTimestamp":1738959781,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Neurocrine Biosciences(NBIX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由154.00美元调整至148.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08042348031835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":0.0286},{"period":"1month","weight":0.0585},{"period":"3month","weight":0.3766},{"period":"6month","weight":0.2907},{"period":"1year","weight":0.3352},{"period":"ytd","weight":0.2393}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，致力于发现、开发及商业化针对未充分解决的神经、精神、内分泌及免疫系统疾病的治疗方法。其产品组合涵盖美国食品药品监督管理局批准用于治疗迟发性运动障碍、亨廷顿病相关舞蹈病、经典先天性肾上腺皮质增生症、子宫内膜异位症及子宫肌瘤的疗法，并在核心治疗领域拥有从小分子到基因疗法的多元化在研管线。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.064262},{"month":2,"riseRate":0.3,"avgChangeRate":-0.015369},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008794},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.012154},{"month":5,"riseRate":0.6,"avgChangeRate":0.054007},{"month":6,"riseRate":0.548387,"avgChangeRate":0.02095},{"month":7,"riseRate":0.516129,"avgChangeRate":-0.000533},{"month":8,"riseRate":0.533333,"avgChangeRate":0.022782},{"month":9,"riseRate":0.566667,"avgChangeRate":0.02711},{"month":10,"riseRate":0.566667,"avgChangeRate":0.029718},{"month":11,"riseRate":0.6,"avgChangeRate":0.039502},{"month":12,"riseRate":0.633333,"avgChangeRate":0.040009}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}